Sanofi Uroxatral Claim Construction Gets Judge's Nod

Law360, New York (May 20, 2009, 12:00 AM EDT) -- A federal judge has handed down a claim construction order for one of the patents in Sanofi-Aventis’ multidistrict litigation alleging Mylan Pharmaceuticals Inc. and other generic-drug manufacturers have infringed its technology covering its prostate treatment, Uroxatral.

Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware on Wednesday rejected several proposed constructions by the generic-drug makers for Sanofi’s U.S. Patent Number 4,661,491, titled “Alfuzosine compositions and use.”

The judge agreed with Sanofi that the term “dysuria” should be construed as “painful or...
To view the full article, register now.